BAY 2927088（Sevabertinib) is the first non-covalent, potent, oral, selective, and reversible inhibitor of tyrosine kinase that potently inhibits mutant HER2 and mutant EGFR in preclinical models. It targets Exon 20 insertions in non-small-cell lung carcinoma (NSCLC) patients.

BAY 2927088（Sevabertinib) is the first non-covalent, potent, oral, selective, and reversible inhibitor of tyrosine kinase that potently inhibits mutant HER2 and mutant EGFR in preclinical models. It targets Exon 20 insertions in non-small-cell lung carcinoma (NSCLC) patients.

Puromycin (CL13900, Puromycine) is an antibiotic, analog of the 3′ end of aminoacyl-tRNA and an inhibitor of protein synthesis that mimics tyrosyl-tRNA, causing premature termination of translation. It blocks translation by labeling and releasing elongating polypeptide chains from ribosomes and has been widely used in molecular biology research.

Cl-amidine hydrochloride is an orally active peptidylarginine deminase (PAD) inhibitor, with IC50 values of 0.8 μM, 6.2 μM and 5.9 μM for PAD1, PAD3, and PAD4, respectively. Cl-amidine hydrochloride induces apoptosis in cancer cells. Cl-amidine hydrochloride induces microRNA (miR)-16 (miRNA-16, microRNA-16) expression and causes cell cycle arrest. Cl-Amidine hydrochloride prevents histone 3 citrullination and neutrophil […]

Cl-amidine hydrochloride is an orally active peptidylarginine deminase (PAD) inhibitor, with IC50 values of 0.8 μM, 6.2 μM and 5.9 μM for PAD1, PAD3, and PAD4, respectively. Cl-amidine hydrochloride induces apoptosis in cancer cells. Cl-amidine hydrochloride induces microRNA (miR)-16 (miRNA-16, microRNA-16) expression and causes cell cycle arrest. Cl-Amidine hydrochloride prevents histone 3 citrullination and neutrophil […]

JNJ-75276617 (Bleximenib, Menin-MLL inhibitor 24) is an orally bioavailable, potent inhibitor of menin targeting the menin-KMT2A selective protein-protein interaction. It also acts as an inhibitor of menin-mixed-lineage leukemia 1 (menin-MLL). JNJ-75276617 displays highly potent antiproliferative activity across several acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) cell lines and patient samples.

Cl-amidine hydrochloride is an orally active peptidylarginine deminase (PAD) inhibitor, with IC50 values of 0.8 μM, 6.2 μM and 5.9 μM for PAD1, PAD3, and PAD4, respectively. Cl-amidine hydrochloride induces apoptosis in cancer cells. Cl-amidine hydrochloride induces microRNA (miR)-16 (miRNA-16, microRNA-16) expression and causes cell cycle arrest. Cl-Amidine hydrochloride prevents histone 3 citrullination and neutrophil […]

Cl-amidine hydrochloride is an orally active peptidylarginine deminase (PAD) inhibitor, with IC50 values of 0.8 μM, 6.2 μM and 5.9 μM for PAD1, PAD3, and PAD4, respectively. Cl-amidine hydrochloride induces apoptosis in cancer cells. Cl-amidine hydrochloride induces microRNA (miR)-16 (miRNA-16, microRNA-16) expression and causes cell cycle arrest. Cl-Amidine hydrochloride prevents histone 3 citrullination and neutrophil […]

JNJ-75276617 (Bleximenib, Menin-MLL inhibitor 24) is an orally bioavailable, potent inhibitor of menin targeting the menin-KMT2A selective protein-protein interaction. It also acts as an inhibitor of menin-mixed-lineage leukemia 1 (menin-MLL). JNJ-75276617 displays highly potent antiproliferative activity across several acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) cell lines and patient samples.

JNJ-75276617 (Bleximenib, Menin-MLL inhibitor 24) is an orally bioavailable, potent inhibitor of menin targeting the menin-KMT2A selective protein-protein interaction. It also acts as an inhibitor of menin-mixed-lineage leukemia 1 (menin-MLL). JNJ-75276617 displays highly potent antiproliferative activity across several acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) cell lines and patient samples.